PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32492159-2	2020	The predominant BTK inhibitors tether irreversibly by covalently binding to cysteine 481 in the BTK catalytic domain.	Cysteine	76-84	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	16-19	
32492159-2	2020	The predominant BTK inhibitors tether irreversibly by covalently binding to cysteine 481 in the BTK catalytic domain.	Cysteine	76-84	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	96-99	
34662393-3	2022	However, resistance to covalently binding BTK inhibitors can develop by a mutation in cysteine 481 of BTK (C481S), which prevents the irreversible binding of the drugs.	Cysteine	86-94	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	42-45	
34662393-3	2022	However, resistance to covalently binding BTK inhibitors can develop by a mutation in cysteine 481 of BTK (C481S), which prevents the irreversible binding of the drugs.	Cysteine	86-94	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	102-105